Larry Luxner, senior correspondent for Rare Disease Advisor, interviews Jason Tardio, chief operating officer at Ovid Therapeutics, which is pursuing therapies for rare epilepsies such as Dravet syndrome and Lennox-Gastaut syndrome.
Read the full story here: Ovid and Takeda Bank on Soticlestat as Novel Therapy for Dravet, Lennox-Gastaut Syndromes
